GlobeNewswire: Arbutus Biopharma Corporation Contains the last 10 of 416 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:32:34ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/08/2843053/0/en/Arbutus-to-Participate-in-Two-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=11918Arbutus to Participate in Two Upcoming Investor Conferences2024-03-08T12:30:00Z<![CDATA[WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:]]>https://www.globenewswire.com/news-release/2024/02/29/2837875/0/en/Arbutus-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=11918Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update2024-02-29T12:30:00Z<![CDATA[On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101]]>https://www.globenewswire.com/news-release/2024/02/15/2829843/0/en/Arbutus-to-Report-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provide-Corporate-Update.html?f=22&fvtc=4&fvtv=11918Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update2024-02-15T12:30:00Z<![CDATA[WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024. The schedule for the press release and conference call/webcast are as follows:]]>https://www.globenewswire.com/news-release/2024/01/08/2805327/0/en/Arbutus-Announces-2024-Corporate-Objectives-and-Provides-Financial-Update.html?f=22&fvtc=4&fvtv=11918Arbutus Announces 2024 Corporate Objectives and Provides Financial Update2024-01-08T12:30:00Z<![CDATA[Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024]]>https://www.globenewswire.com/news-release/2023/11/09/2777768/0/en/Arbutus-Biopharma-and-Barinthus-Bio-Present-Preliminary-Data-from-Phase-2a-Clinical-Trial-Combining-Imdusiran-with-VTP-300-at-AASLD-The-Liver-Meeting.html?f=22&fvtc=4&fvtv=11918Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®2023-11-09T21:01:00Z<![CDATA[The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline]]>https://www.globenewswire.com/news-release/2023/11/08/2776111/0/en/Arbutus-to-Present-at-Jefferies-London-Healthcare-Conference.html?f=22&fvtc=4&fvtv=11918Arbutus to Present at Jefferies London Healthcare Conference2023-11-08T12:30:00Z<![CDATA[WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference:]]>https://www.globenewswire.com/news-release/2023/11/07/2774965/0/en/Arbutus-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=11918Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update2023-11-07T12:30:00Z<![CDATA[Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV antigen-specific immunotherapy]]>https://www.globenewswire.com/news-release/2023/11/07/2774954/0/en/Arbutus-Announces-CEO-William-Collier-to-Retire-December-31-2023.html?f=22&fvtc=4&fvtv=11918Arbutus Announces CEO, William Collier, to Retire December 31, 20232023-11-07T12:15:00Z<![CDATA[Michael J. McElhaugh, Arbutus Co-founder and COO, to Serve as Interim CEO]]>https://www.globenewswire.com/news-release/2023/10/24/2765485/0/en/Arbutus-to-Report-Third-Quarter-2023-Financial-Results-and-Provide-Corporate-Update.html?f=22&fvtc=4&fvtv=11918Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update2023-10-24T11:30:00Z<![CDATA[WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its third quarter 2023 financial results and corporate update for Tuesday, November 7, 2023. The schedule for the press release and conference call/webcast are as follows:]]>https://www.globenewswire.com/news-release/2023/10/18/2762227/0/en/Arbutus-to-Present-at-H-C-Wainwright-4th-Annual-Hepatitis-B-Virus-HBV-Virtual-Conference.html?f=22&fvtc=4&fvtv=11918Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference2023-10-18T11:30:00Z<![CDATA[WARMINSTER, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference:]]>